-
SRGN overexpression promoted colorectal cancer cell migration and invasion and SRGN was physically binding to a hypoxia response element in its promoter region.
-
SRGN secreted by tumor cells and stromal components in the TME promotes malignant phenotypes through interacting with tumor cell receptor CD44
-
Extracellular spce serglycin upregulated CD44 receptor expression to maintain nasopharyngeal carcinoma stemness by interacting with CD44 and activating the MAPK/beta-catenin pathway.
-
SRGN expression is significantly upregulated in human masticatory mucosa during wound healing
-
Patients with NPC with tumors showing strong tumor intensity and low infiltrated percentage of tumor-infiltrated lymphocytes with serglycin may be at high risk for distant metastases.
-
The elevated levels of serglycin in aggressive cancer and stromal cells may suggest a key role for serglycin in disease progression
-
These results suggest functions for serglycin in endothelial cells trough interactions with partner molecules, in biological processes with relevance for diabetic complications, cardiovascular disease and cancer development.
-
These results suggest that different signaling pathways are involved in regulating secretion of serglycin and partner molecules in activated endothelial cells.
-
The reduced expression of SRGN was accompanied by elevated levels of E-cadherin.
-
These studies provide direct evidence for a critical role for serglycin in MM pathogenesis and show that targeting serglycin may provide a novel therapeutic approach for MM.
-
These results suggest that human epicardial adipose tissue (EAT) has strong inflammatory properties in patients with coronary artery disease and provide novel evidence that serglycin is an adipocytokine highly expressed in EAT.
-
Cell-surface SRGN promotes the adhesion of myeloma cells to collagen type I.
-
This review covers recent studies on the involvement of serglycin in various pathological conditions, as well as its roles in immunity, hemostasis, cell growth, apoptosis, and reproduction.
-
Human granulocyte precursors transfected with siRNA against serglycin displayed reduced capability to retain fully processed HNP-1.
-
Serglycin regulates NPC metastasis via autocrine and paracrine routes, and that it serves as an independent prognostic indicator of metastasis-free survival and disease-free survival in NPC patients.
-
Serglycin secreted by human multiple myeloma cell lines inhibits both the classical and lectin pathways of complement, without influencing alternative pathway activity.
-
Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1.
-
proapoptotic granzyme is exocytosed predominantly as a macromolecular complex with serglycin
-
cell- and differentiation-specific alterations in chromatin structure may control serglycin gene expression
-
serglycin-bound granzyme B in high-molecular-weight degranulate material from cytotoxic T lymphocytes predominantly followed a dynamin-dependent pathway to kill target cells
